ED50 of Cis-atracurium for Laryngeal Mask Incubation in General Anesthesia

Sponsor
China International Neuroscience Institution (Other)
Overall Status
Completed
CT.gov ID
NCT03668262
Collaborator
(none)
35
1
4.5
7.8

Study Details

Study Description

Brief Summary

  1. The muscle relaxants can improve the conditions of laryngeal mask incubation and reduce the related complications (such as laryngeal spasm and postoperative throat pain)

  2. The dosages of muscle relaxants used in various researches vary greatly.

  3. We are planning use the most classical method for determining the ED50 or half effective concentration of cis-atracurium using sequential method, which is also called " up and down method" and " ladder method".

Condition or Disease Intervention/Treatment Phase

Detailed Description

The concordance of the current research is that muscle relaxants can improve the conditions of laryngeal mask incubation and reduce the related complications (such as laryngeal spasm and postoperative throat pain ) of laryngeal mask incubation. It is necessary to use muscle relaxants in laryngeal mask incubation under non-special circumstances. However, the dosages of muscle relaxants used in various researches vary greatly of normal endotracheal intubation. Previous studies have shown that the amount of muscle relaxant required for laryngeal mask intubation is smaller than that required for endotracheal intubation. Although the dosage of muscle relaxant required for tracheal intubation can ensure the smooth insertion of laryngeal mask airway, laryngeal mask airway is mostly used for short surgery, which is prone to postoperative muscle relaxation residue and prolongs the recovery. We planning use the most classical method for determining the ED50 or half effective concentration of cis-atracurium using sequential method, which is also called " up and down method" and " ladder method".

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
35 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
ED50 of Cis-atracurium for Laryngeal Mask Incubation in General Anesthesia During Urology Surgery
Actual Study Start Date :
Sep 15, 2018
Actual Primary Completion Date :
Jan 30, 2019
Actual Study Completion Date :
Jan 30, 2019

Arms and Interventions

Arm Intervention/Treatment
0.15mg/ kg group

Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.

Drug: Cis-atracurium
Different concentration of cis-atracurium
Other Names:
  • muscle relaxants
  • 0.1mg/ kg group

    Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.15/1.5=0.1 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)

    Drug: Cis-atracurium
    Different concentration of cis-atracurium
    Other Names:
  • muscle relaxants
  • 0.07mg/ kg group

    Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.1/1.5=0.0667 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)

    Drug: Cis-atracurium
    Different concentration of cis-atracurium
    Other Names:
  • muscle relaxants
  • 0.05mg/ kg group

    Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.07/1.5=0.0466( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)

    Drug: Cis-atracurium
    Different concentration of cis-atracurium
    Other Names:
  • muscle relaxants
  • 0.03mg/ kg group

    Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.05/1.5=0.0333 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)

    Drug: Cis-atracurium
    Different concentration of cis-atracurium
    Other Names:
  • muscle relaxants
  • 0.02mg/ kg group

    Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.03/1.5=0.02( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)

    Drug: Cis-atracurium
    Different concentration of cis-atracurium
    Other Names:
  • muscle relaxants
  • Outcome Measures

    Primary Outcome Measures

    1. Laryngeal mask insertion conditions(satisfactory/unsatisfactory) [through study completion, an average of 1 day]

      The evaluation criteria of laryngeal mask insertion conditions are based on siva lingam's six-point three-level table, which is evaluated from the following six aspects: the degree of mouth opening, difficulty in laryngeal mask insertion, cough, retch, laryngeal spasm, and body movement. Each item is divided into 3, 2 and 1 points according to the degree of severity, with a full score of 18 points, 16 points and above being satisfactory, and 16 points and below being unsatisfactory.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    25 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. ASA Ⅱ~Ⅲlevel;

    2. BMI18.5-30;

    3. Those who intend to undergo short urological surgery ( operation time < 1h );

    4. Age 25~75 years

    5. Estimated amount of bleeding < 5ml / kg.

    Exclusion Criteria:
    1. Neuromuscular diseases or metabolic diseases;

    2. Preoperative complicated with water and electrolytes disorders ( such as hypokalemia and hypocalcemia );

    3. Serious hepatic and renal insufficiency and serious heart and lung diseases;

    4. Predictable difficult airway;

    5. Take drugs ( such as aminoglycoside, polymyxin, phenytoin sodium, carbamazepine, etc. ) that affect the nerve-muscle transmission function or the efficacy of muscle relaxants before surgery;

    6. Muscle relaxation drug allergy;

    7. Previous history of alcoholism or drug abuse.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Xuanwu Hospital Beijing Beijing China 100053

    Sponsors and Collaborators

    • China International Neuroscience Institution

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    China International Neuroscience Institution
    ClinicalTrials.gov Identifier:
    NCT03668262
    Other Study ID Numbers:
    • CINI-AD-20180808
    First Posted:
    Sep 12, 2018
    Last Update Posted:
    Jan 22, 2020
    Last Verified:
    Jan 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 22, 2020